ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

0J7G Hutchison China Meditech Ltd

33.29
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Hutchison China Meditech Ltd 0J7G London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 33.29 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
33.29 33.29
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/1/202401:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
29/12/202302:30UKREGHutchmed (China) Limited Total Voting Rights
29/12/202302:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
21/12/202304:00UKREGHutchmed (China) Limited Overseas Regulatory Announcement
13/12/202301:00RNSNONHutchmed (China) Limited Inclusion in National Reimbursement..
07/12/202304:04UKREGHutchmed (China) Limited Overseas Regulatory Announcement
01/12/202301:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30/11/202302:30UKREGHutchmed (China) Limited Total Voting Rights
09/11/202301:00UKREGHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM)..
24/10/202303:30UKREGHutchmed (China) Limited Vesting of awards under the LTIP
16/10/202303:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29/9/202303:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
29/9/202303:30UKREGHutchmed (China) Limited Total Voting Rights
14/9/202303:30UKREGHutchmed (China) Limited Director's Share Dealing
12/9/202303:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12/9/202301:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
31/8/202303:30UKREGHutchmed (China) Limited Total Voting Rights
29/8/202301:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
21/8/202301:00UKREGHutchmed (China) Limited Sovleplenib Phase 3 Study Meets..
07/8/202303:30UKREGHutchmed (China) Limited Exercise of Share Options by a..
31/7/202306:00UKREGHutchmed (China) Limited Interim Results and Business..
20/7/202301:00RNSNONHutchmed (China) Limited Breakthrough Therapy Designation..
13/7/202303:30UKREGHutchmed (China) Limited Changes to Board and Technical..
10/7/202301:00RNSNONHutchmed (China) Limited Phase 1 Study of HMPL-415 Initiated
29/6/202303:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
26/6/202303:30UKREGHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year..
16/6/202301:00UKREGHutchmed (China) Limited Phase III FRESCO-2 Results in The..
15/6/202309:39UKREGHutchmed (China) Limited MAA of Fruquintinib Validated by..
09/6/202304:30RNSNONHutchmed (China) Limited HUTCHMED Highlights Presentations..
06/6/202304:00UKREGHutchmed (China) Limited LTIP and Share Option Scheme
31/5/202303:30UKREGHutchmed (China) Limited Total Voting Rights
26/5/202301:00RNSNONHutchmed (China) Limited HUTCHMED Highlights Presentations..
26/5/202301:00UKREGHutchmed (China) Limited Fruquintinib NDA Granted Priority..
17/5/202303:30UKREGHutchmed (China) Limited Standard form for notification of..
12/5/202307:15UKREGHutchmed (China) Limited Annual General Meeting Poll Results
12/5/202303:30UKREGHutchmed (China) Limited Board of Directors and Board..
10/5/202303:30UKREGHutchmed (China) Limited Appointment of Independent NED

Su Consulta Reciente

Delayed Upgrade Clock